{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ATRIPLA", "query": { "intervention": "ATRIPLA" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ATRIPLA&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T13:38:57.317Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01095796", "title": "Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" }, { "name": "Atripla", "type": "DRUG" }, { "name": "Stribild Placebo", "type": "DRUG" }, { "name": "Atripla Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 707, "start_date": "2010-03", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-11-11", "last_synced_at": "2026-09-07T13:38:57.317Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01095796" }, { "nct_id": "NCT00984152", "title": "Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infections" ], "interventions": [ { "name": "TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily", "type": "DRUG" }, { "name": "TDF/FTC + Efavirenz (Atripla) Once-Daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 0, "start_date": "2011-06", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2015-05-06", "last_synced_at": "2026-09-07T13:38:57.317Z", "location_count": 5, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00984152" }, { "nct_id": "NCT02556268", "title": "Interaction With HIV Antiretroviral Agents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-DDI" ], "interventions": [ { "name": "Riociguat (Adempas, BAY 63-2521)", "type": "DRUG" }, { "name": "ATRIPLA", "type": "DRUG" }, { "name": "COMPLERA", "type": "DRUG" }, { "name": "STRIBILD", "type": "DRUG" }, { "name": "TRIUMEQ", "type": "DRUG" }, { "name": "Antiretroviral protease inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2016-02-23", "completion_date": "2016-12-07", "has_results": false, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-09-07T13:38:57.317Z", "location_count": 2, "location_summary": "Orlando, Florida • Boston, Massachusetts", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02556268" }, { "nct_id": "NCT01978743", "title": "Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV", "HIV-associated Neurocognitive Disorder", "Neurotoxicity" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2014-01", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-09-07T13:38:57.317Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01978743" }, { "nct_id": "NCT01929759", "title": "Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Disease" ], "interventions": [ { "name": "Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2014-01", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-07-28", "last_synced_at": "2026-09-07T13:38:57.317Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01929759" }, { "nct_id": "NCT01270802", "title": "Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Tenofovir/emtricitabine", "type": "DRUG" }, { "name": "Tenofovir/emtricitabine/efavirenz", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2011-04", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-09-07T13:38:57.317Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01270802" }, { "nct_id": "NCT00414635", "title": "FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Intermitent Dosing", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Community Research Initiative of New England", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2006-08", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-09-07T13:38:57.317Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00414635" }, { "nct_id": "NCT00775606", "title": "Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acquired Immune Deficiency Syndrome" ], "interventions": [ { "name": "Lopinavir 400 mg/ritonavir 100 mg", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 15, "start_date": "2008-10", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-09-07T13:38:57.317Z", "location_count": 4, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00775606" }, { "nct_id": "NCT01515813", "title": "Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Pravastatin sodium", "type": "DRUG" }, { "name": "Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2011-11", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2016-02-01", "last_synced_at": "2026-09-07T13:38:57.317Z", "location_count": 9, "location_summary": "Los Angeles, California • Torrance, California • St Louis, Missouri + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01515813" }, { "nct_id": "NCT02345226", "title": "Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/RPV/TAF", "type": "DRUG" }, { "name": "EFV/FTC/TDF Placebo", "type": "DRUG" }, { "name": "EFV/FTC/TDF", "type": "DRUG" }, { "name": "FTC/RPV/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 881, "start_date": "2015-01-26", "completion_date": "2019-01-02", "has_results": true, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-09-07T13:38:57.317Z", "location_count": 79, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02345226" } ] }